InvestorsHub Logo
Followers 27
Posts 744
Boards Moderated 0
Alias Born 07/12/2012

Re: biopharm post# 299412

Monday, 06/12/2017 3:29:56 PM

Monday, June 12, 2017 3:29:56 PM

Post# of 346050
Bio, my point has always been that retail is the last to know anything.

PPHM RNA line sequencing, betabodies potential, Bavi tripling the anti-PD1 footprint, exosome PS vesicle count and characterization: we're just not privy to ANY of the discussions regarding this pivotal biotech.

Look, Wolchok's melanoma work STARTED I/O 1.O. And then he picks a Tustin microtech as his centerpiece for I/O 2.0

What gives? Fact is, we don't know. Except for one thing. All the KOLs have Bavi and the PS platform right in the middle of the discussion.

Best,

Joe 6





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News